10. Danaher (life sciences & diagnostics segments)
10. Danaher (life sciences & diagnostics segments)$13,512,600,000*
Washington, D.C.
2019 rank: 8
*Fiscal year ended 12/31/2019
Even without the COVID-19 pandemic, this has been a year of change at Danaher. The company near the end of last year completed the spinout of its dental business into a new company called Envista, closed its $20 billion purchase of GE’s Biopharma business in March, and then-EVP Rainer M. Blair moved up to the corner office after Thomas P. Joyce Jr.’s retirement as CEO on Sept. 1. The company has especially played an important role against the coronavirus when it comes to diagnostics. Danaher’s Cepheid business recently launched rapid 4-in-1 combination tests for COVID-19, Flu A, Flu B and RSV from a single patient sample, and the company’s Beckman Coulter Diagnostics has assays to detect severe inflammatory response from COVID-19 as well as antibodies associated with the virus. – CN
Key personnel: Rainer Blair, president & CEO; Daniel Comas, EVP; Matt McGrew, EVP & CFO; Joakim Weidemanis, EVP; Brian Ellis, SVP & general counsel; William King, SVP, strategic development; Angela Lalor, SVP, human resources; Robert Lutz, SVP & chief accounting officer; Daniel Raskas, SVP, corporate development
